Florence Hourcade‐Potelleret

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

Timothy P. Hughes, Michael J. Mauro, Jörge E. Cortes et al. · New England Journal of Medicine · 2019 · 467 citations · Full text

Medicine, Oncology, Pharmacology +9

Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study

Antonio Salar, Irit Avivi, Beate Bittner et al. · Journal of Clinical Oncology · 2014 · 93 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacotherapy +17

A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors.

Dejan Juric, Jean‐Charles Soria, Sunil Sharma et al. · Journal of Clinical Oncology · 2014 · 54 citations

Medicine, Oncology, Pharmacology +14

Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia

Nobuko Hijiya, Alexey Maschan, Carmelo Rizzari et al. · Blood · 2019 · 51 citations · Full text

Medicine, Hematology, Oncology +12

Development of a Subcutaneous Formulation for Trastuzumab - Nonclinical and Clinical Bridging Approach to the Approved Intravenous Dosing Regimen

Beate Bittner, W. Richter, Florence Hourcade‐Potelleret et al. · Arzneimittelforschung · 2012 · 50 citations

Pharmacy, Pharmacokinetics, Pharmacology +17